Centre includes includes dexamethasone drug in COVID-19 treatment protocol for moderate to severe cases

The updated protocol includes the advice to use dexamethasone as an alternative choice to methylprednisolone for managing moderate to severe cases of COVID-19.

Press Trust of India June 27, 2020 17:49:45 IST
Centre includes includes dexamethasone drug in COVID-19 treatment protocol for moderate to severe cases

New Delhi: An inexpensive, widely used steroid dexamethasone was included in the treatment protocols for COVID-19 patients in moderate to severe stages of illness among other therapeutic measures by the Union health ministry on Saturday.

The updated protocol includes the advice to use dexamethasone as an alternative choice to methylprednisolone for managing moderate to severe cases of COVID-19 . The change has been made after considering the latest available evidence and expert consultation, the ministry said.

According to the revised 'Clinical Management Protocols for COVID-19 ', dexamethasone which is already used in treating lung infections besides in a wide range of conditions for its anti-inflammatory and immunosuppressant effects can be used as an alternative to methylprednisolone which already existed in the treatment guidelines.

Centre includes includes dexamethasone drug in COVID19 treatment protocol for moderate to severe cases

Representational image. AP

The health ministry on 13 June had also allowed the use of antiviral drug remdesivir for restricted emergency use and off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in moderate stage of the illness as an investigational therapy.

Follow Latest updates on coronavirus Outbreak here

It also recommended hydroxychloroquine in patients during the early course of the disease and not on critically ill patients.

The use of these drugs continues to be included in the revised treatment protocols under the 'investigational therapy'.

The revised treatment protocols for moderate cases advised considering methylprednisolone 0.5 to 1 mg/kg or dexamethasone 0.1 to 0.2 mg/kg for three days, preferably within 48 hours of admission or if oxygen requirement is increasing and if inflammatory markers are increased. The duration of administration should be reviewed as per clinical response.

For patients having respiratory distress requiring mechanical ventilation, both non- invasive and invasive, the ministry said methylprednisolone 1 to 2mg/kg/day or dexamethasone 0.2 to 0.4 mg/kg per day should be considered for 5-7 days in two divided doses, if not given already.

"Note that a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive effects," the treatment protocols stated.

The revised treatment protocols were issued as India's COVID-19 tally raced past the five-lakh mark on Saturday with the biggest single-day surge of 18,552 cases while the death toll climbed to 15,685 with 384 fatalities, the updated figure at 8 am showed.

According to WHO, the corticosteroid dexamethasone was tested in hospitalised patients with COVID-19 in the United Kingdom's national clinical trial 'RECOVERY' and was found to have benefits for critically ill patients.

According to preliminary findings shared with WHO, for patients on ventilators, the treatment was shown to reduce mortality by about one-third, and for patients requiring only oxygen, mortality was cut by about one-fifth.

Updated Date:

also read

COVID-19 news update: Centre defends increasing gap between doses; report claims 'underreporting' of deaths in Chennai
India

COVID-19 news update: Centre defends increasing gap between doses; report claims 'underreporting' of deaths in Chennai

On the vaccine front, India's vaccination drive seemed set to get another push with SII announcing that it hopes to launch Novavax’s COVID-19 vaccine ‘Covovax’ in India by September

COVID Updates: Daily cases decline by 78% decline since May peak; ICMR to start national sero survey
India

COVID Updates: Daily cases decline by 78% decline since May peak; ICMR to start national sero survey

Citing the sustained decline in daily coronavirus cases, the Centre said the COVID-19 situation in the country 'appears to be stabilising'

Covishield dose gap row: Harsh Vardhan says decision was taken unanimously; calls controversy 'unfortunate'
India

Covishield dose gap row: Harsh Vardhan says decision was taken unanimously; calls controversy 'unfortunate'

Covishield dose gap row: Union health minister Harsh Vardhan too said the decision to increase the gap “has been taken in a transparent manner based on scientific data”